Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Kronos Bio ( (KRON) ) has provided an update.
On June 20, 2025, Kronos Bio, Inc. completed a merger with Concentra Biosciences, LLC, through Concentra’s subsidiary, Merger Sub. The merger involved a tender offer where Kronos Bio’s outstanding shares were exchanged for cash and contingent value rights, with the merger resulting in Kronos becoming a wholly owned subsidiary of Concentra. Following the merger, Kronos Bio’s shares were delisted from Nasdaq, and the company filed to terminate its registration and reporting obligations with the SEC.
The most recent analyst rating on (KRON) stock is a Buy with a $2.25 price target. To see the full list of analyst forecasts on Kronos Bio stock, see the KRON Stock Forecast page.
Spark’s Take on KRON Stock
According to Spark, TipRanks’ AI Analyst, KRON is a Neutral.
Kronos Bio’s overall stock score reflects its significant revenue growth but ongoing unprofitability and financial challenges. Corporate events provide a positive outlook with potential cost savings and shareholder value enhancement. Technical analysis suggests mixed market sentiment with some bearish indicators. The valuation remains speculative given the negative earnings and lack of dividend.
To see Spark’s full report on KRON stock, click here.
More about Kronos Bio
Kronos Bio, Inc. operates in the biotechnology industry, focusing on the development of novel cancer therapeutics. The company is engaged in discovering and developing therapies that target dysregulated transcription factors and other cancer drivers.
Average Trading Volume: 868,587
Technical Sentiment Signal: Sell
Current Market Cap: $52.87M
For a thorough assessment of KRON stock, go to TipRanks’ Stock Analysis page.